Traws Pharma says UK MHRA review defers Phase 2a influenza challenge study for tivoxavir marboxil

• Traws Pharma deferred a planned Phase 2a human influenza challenge study of tivoxavir marboxil following a negative review by the UK MHRA.
• The setback delays the program’s near-term clinical timeline, shifting focus to backup influenza antiviral candidates designed to address regulatory concerns.
• Management cited cash runway extending to Q1 2027 while it advances alternative long-acting influenza compounds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-073593), on June 12, 2026, and is solely responsible for the information contained therein.